ABOUT METHYLATION & B12 METABOLISM

Fatigue, cognitive issues, neurological symptoms. They might trace back to B12 and folate metabolism — and rare variants most tests miss.

Whole genome sequencing identifies rare pathogenic variants in folate and B12 metabolism that cause severe neurological disease, distinguishing them from common variants with debated clinical significance.

MTHFR
MTR
MTRR
CBS

About this condition

Methylation & B12 Metabolism

The folate, methylation, and cobalamin (B12) metabolism pathways are central to DNA synthesis, methylation reactions, and energy metabolism. These pathways involve multiple genes including MTHFR, which encodes methylenetetrahydrofolate reductase; MTR, encoding methionine synthase; MTRR, encoding methionine synthase reductase; and CBS, encoding cystathionine β-synthase. Genetic variants in these genes can disrupt the pathway, but the clinical significance depends critically on variant type: rare biallelic loss-of-function variants cause severe disease, while common polymorphisms have limited proven clinical utility despite widespread testing.

The most frequently tested variant is MTHFR C677T, a polymorphism present in approximately 10-15% of Caucasians homozygously (TT genotype), ~25% of Hispanic populations, with varying frequencies across other ancestries. Despite its prevalence, ACMG guidelines issued in 2013 explicitly recommend AGAINST routine MTHFR genotyping for thrombophilia or recurrent pregnancy loss, noting that homocysteine level measurement is more clinically actionable than genotype alone. The clinical impact of common MTHFR, MTR, and MTRR polymorphisms on thrombosis, cardiovascular disease, and recurrent pregnancy loss has been largely disproven by recent large meta-analyses.

In contrast, rare pathogenic variants in these genes cause distinct clinical entities with profound neurological consequences. Biallelic MTHFR deficiency causes severe homocysteinuria (plasma homocysteine often >100 μmol/L; normal <15 μmol/L), associated with developmental delay, seizures, thrombosis, and vision loss. CBS deficiency similarly produces markedly elevated homocysteine and neurological disease. Identification of rare biallelic variants enables specific treatment: high-dose folate and B12 supplementation, betaine therapy for certain forms, and dietary methionine restriction can prevent or slow neurological deterioration when diagnosed early.

MTHFR variants span a spectrum: common polymorphisms with minimal clinical effect and rare biallelic loss-of-function mutations causing severe homocystinuria — WGS captures both to enable proper clinical interpretation.

Gene locus: MTHFR (1p36.22), MTR (1q43), MTRR (5p15.31), CBS (21q22.3)

Standard panels test common polymorphisms with debated utility. They risk missing rare pathogenic variants that cause severe neurological disease.

Common variants dominate testing despite limited clinical evidence

Standard one-carbon metabolism panels focus on common polymorphisms like MTHFR C677T, MTR 2756A>G, and MTRR 66A>G. These variants are present in significant percentages of the population but their clinical consequences remain disputed. Large meta-analyses have failed to establish strong associations between these common variants and thrombosis, cardiovascular disease, or recurrent pregnancy loss. The ACMG issued explicit guidance against routine MTHFR testing for these indications, yet testing remains widespread. Whole genome sequencing captures not only common variants but also rare pathogenic variants that definitively cause disease — enabling clinicians to distinguish between benign polymorphisms and disease-causing mutations requiring immediate intervention.

Rare mutations demand detection before neurological damage develops

Biallelic loss-of-function variants in MTHFR, MTR, MTRR, or CBS cause severe homocystinuria with plasma homocysteine exceeding 100 μmol/L, typically accompanied by neurological symptoms including developmental delay, seizures, vision loss, and thrombosis. Early identification of these rare variants enables life-changing intervention: high-dose folate and B12 supplementation, betaine therapy, and dietary modification can prevent or dramatically slow neurological deterioration. Standard panels testing only common polymorphisms miss these critical rare variants entirely. WGS provides comprehensive detection of all variants in the pathway, enabling proper distinction between benign polymorphisms and disease-causing mutations requiring urgent treatment.

Fatigue, cognitive issues, neurological symptoms. They might trace back to B12 and folate metabolism — and rare variants most tests miss.

Methylation & B12 Metabolism

Standard panels test common polymorphisms with debated utility. They risk missing rare pathogenic variants that cause severe neurological disease.

Common variants dominate testing despite limited clinical evidence

Rare mutations demand detection before neurological damage develops

Others in Metabolic

One test. A lifetime of answers.